OCT 19, 2021
Straight from the Cutter’s Mouth
0.5 General AMA PRA Category 1 Credits™
Dr. Thomas Ciulla joins to discuss developing a career as a researcher and transitioning to industry and major coming advances in delivery of retina therapeutic agents.
Relevant Financial Disclosures:
Dr. Sridhar is a consultant for Genentech, Regeneron, Allergan, Alcon, and Dorc. Dr. Ciulla is the Chief Medical Officer and Chief Development Officer at Clearside Bio.
Release: October 19, 2021; expires October 19, 2024
Reviewers: Carl Danzig, MD
Disclosures: The physician reviewers and Academy staff report no relevant financial disclosures.
Learning Objective: Upon completion of this episode, the listener should be able to describe evolving standards of care for the management of vitreoretinal disorders or the outcomes from recent research and how these impact patient care decisions.
Audience: This activity is intended for retina subspecialists and comprehensive ophthalmologists.
Accreditation: The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Academy of Ophthalmology designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits.TM Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hardware/Software Requirements: This learning activity requires a current web browser and speaker or headset capable of playing streaming audio.